Mn Services Vermogensbeheer B.V. Purchases 3,900 Shares of Amgen Inc. $AMGN

Mn Services Vermogensbeheer B.V. grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 204,892 shares of the medical research company’s stock after buying an additional 3,900 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Amgen were worth $57,821,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Investment Solutions LLC bought a new stake in Amgen in the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen in the second quarter worth about $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen in the second quarter valued at approximately $32,000. Quaker Wealth Management LLC raised its position in shares of Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the period. Finally, Nvwm LLC lifted its stake in shares of Amgen by 893.3% during the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after buying an additional 134 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent research reports. Guggenheim lifted their price objective on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Piper Sandler raised their price target on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Bank of America boosted their price objective on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Royal Bank Of Canada raised their target price on Amgen from $330.00 to $335.00 and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Finally, Morgan Stanley reduced their target price on Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $339.24.

Amgen Stock Performance

NASDAQ:AMGN opened at $344.75 on Friday. The stock has a market cap of $185.64 billion, a P/E ratio of 26.64, a PEG ratio of 3.09 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The business’s 50-day moving average price is $332.07 and its two-hundred day moving average price is $307.54. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $349.98.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 77.90%.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 10,908 shares of company stock valued at $3,674,966 in the last quarter. Insiders own 0.76% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.